NCT01392508CompletedNot Applicable
Prospective, Non-interventional, Multi-centre Clinical Study to Assess the Clinical Validity of the Heparin Binding Protein (HBP) Assay for Indicating the Presence, or Outcome, of Severe Sepsis (Including Septic Shock), Over 72 Hours, in Patients With Suspected Infection Following Emergency Department Admission.
Axis Shield Diagnostics Ltd5 sites in 2 countries759 target enrollmentStarted: March 2011Last updated:
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Enrollment
- 759
- Locations
- 5
Study Overview
Brief Summary
The purposes of this study is to determine whether Heparin Binding Protein (HBP) can be used as a marker of severe sepsis (including septic shock) in patients presenting to the emergency department with suspected infection.
Study Design
- Study Type
- Observational
- Observational Model
- Case Only
- Time Perspective
- Prospective
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Greater than or equal to 18 years
- •Suspected Infection
- •one or more SIRS criteria
Exclusion Criteria
- Not provided
Investigators
Study Sites (5)
Loading locations...
Similar Trials
Terminated
Not Applicable
Sepsis Assessment in Belgian Emergency RoomsShock, SepticSevere SepsisSepsisNCT02424721Axis Shield Diagnostics Ltd100
Completed
Not Applicable
Heparin Binding Protein in Early Sepsis DiagnosisInfectionSepsisNCT03295825Hellenic Institute for the Study of Sepsis400
Completed
Not Applicable
Heparin Binding Protein as a Prognostic Biomarker of Sepsis SeverityHBPSepsisNCT05610020Ain Shams University55
Completed
Phase 2
Heparin Binding Protein in Patients With Acute Respiratory Failure Treated With GCSF (Filgrastim)Critically IllAcute Respiratory FailureNCT01713309Helsinki University Central Hospital59
Terminated
Phase 2
Nebulized Heparin for COVID19-associated Acute Respiratory FailureCovid19NCT04842292Brittany Bissell2